Korean Biotech Firms Face Liquidity Squeeze from CB Redemptions
Over 15 Korean biotech firms are accelerating cash outflows as early redemption of convertible bonds surges due to falling share prices, creating immediate liquidity pressures for R&D-dependent companies.
Korean pharmaceutical and biotech companies are experiencing a sharp increase in early redemptions of convertible bonds (CBs), a trend driven by share prices falling below preset conversion levels. According to data from the Financial Supervisory Service, more than 15 listed biotech firms disclosed decisions to acquire self-convertible bonds before their maturity dates this year. This shift forces companies to repay principal and interest in cash rather than issuing new equity, a significant change for firms that rely on continuous funding for research and clinical trials.
The mechanism of CBs dictates that investors convert to shares only when stock prices exceed the conversion price to realize gains. When prices drop below this threshold, it becomes financially advantageous for bondholders to exercise put options or negotiate buybacks. Consequently, companies face earlier-than-expected cash outflows, straining liquidity in a sector where capital preservation is critical for ongoing scientific development.
Major Firms Execute Large-Scale Buybacks
Samsung Pharm executed the largest pre-maturity acquisition among the reported cases. On August 12, the company decided to buy back 20.825 billion won in CBs, a move made roughly one year after issuing 26.9 billion won in such bonds. At the time of the decision, Samsung Pharm’s closing price stood at 1,250 won, approximately 21% below the 1,591 won conversion price, rendering conversion unattractive for investors.
Lunit also engaged in substantial redemptions, acquiring 44.6948 billion won in CBs on September 3. The total payout, including interest, reached 52.36396 billion won. An additional 3.17027 billion won was paid on September 30. Similarly, HLB Pep acquired 8.26 billion won in principal, paying a total of 8.51091 billion won including interest after an investor exercised a put option on September 9.
Deep Discounts Trigger Investor Put Options
Several firms reported stock prices significantly lower than their CB conversion levels, prompting high rates of put option exercises. HLB bioStep conducted two rounds of acquisitions in July and August, with stock prices on payment dates ranging from 1,852 won to 2,540 won. These figures were 76% and 68% below the 7,990 won conversion price, respectively, making cash repayment the preferred outcome for bondholders.
NGeneBio faced an extreme case where 80% of its 3 billion won CB issuance was subject to early redemption. The company repaid the full amount in cash after the stock price fell approximately 75% below the conversion price. Shaperon also saw its closing price drop to 614 won, less than half of its 1,685 won conversion price, highlighting the severity of the discount driving these redemptions.
Liquidity Pressure Impacts R&D Continuity
The immediate cash outflow associated with CB redemptions poses a direct threat to the operational stability of biotech firms. Unlike equity conversion, which preserves cash, bond redemption requires full principal repayment. For companies like Syntekabio, ARIBIO Holdings, and GeneOne Life Science, which are also engaged in these buybacks, the accelerated depletion of cash reserves may constrain their ability to fund essential R&D activities and clinical trials.
As noted in reporting by GN stocks/shares-surge, the aggregate effect of these redemptions is creating a liquidity squeeze across the sector. The shift from potential equity dilution to mandatory cash repayment alters the financial structure of these firms, forcing a reallocation of resources from growth initiatives to debt servicing. This dynamic underscores the vulnerability of biotech companies to market volatility when their funding mechanisms are tied to stock performance.
